Compositions and methods of treatment of cancer
AssigneeMinerva Biotechnologies Corporation
InventorCynthia BAMDAD
Life of this patent
Estimating the term…
Abstract
This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.
Claims6
-9. (canceled)
A method of reducing proliferation of tumor cells that express cleaved form of MUC1 in which MGFR region is accessible to ligand interaction, by contacting the cells with an effective amount of composition, comprising a structure:
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- R1, R2, and R3 each independently comprise at least one atom, and
- R4 comprises a multifused cyclic structure.
-13. (canceled)
A method of reducing proliferation of tumor cells that express cleaved form of MUC1 in which MGFR region is accessible to ligand interaction, by contacting the cells with an effect amount of composition, comprising a structure:
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- R1 comprises at least one atom, and
- R5 comprises a structure including a unit;
- wherein R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 each independently comprise at least one atom,
- J comprises a chemical bond or at least one atom, and
- at least one of R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 is substituted by J.
A method of reducing proliferation of tumor cells that express cleaved form of MUC1 in which MGFR region is accessible to ligand interaction, by contacting the cells with an effective amount of composition, comprising a structure:
- wherein A1, A2, A3, and A4 are each independently selected from the group consisting of H and a halogen,
- R1 comprises at least one atom, and
- R5 comprises a structure including a unit:
- wherein R11, R12, R13, R14, R15, R16, R17, R18, R19, R20 and R21 each independently comprise at least one atom, and
- J comprises a chemical bond or at least one atom.
-43. (canceled)
Dependencies are inferred from the claim text.